Published in Annu Rev Immunol on January 01, 2000
Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults | NCT00043511
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A (2004) 2.03
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol (2001) 1.81
Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol (2007) 1.58
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age. Malar J (2008) 1.45
Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits Mycobacterium smegmatis-induced cytokine production by human macrophages in vitro. Infect Immun (2001) 1.44
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36
Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest (2005) 1.35
Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1. Infect Immun (2005) 1.31
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun (2001) 1.24
Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol (2002) 1.22
CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun (2006) 1.21
T-cell epitope vaccine design by immunoinformatics. Open Biol (2013) 1.20
DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun (2002) 1.19
DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun (2005) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol (2010) 1.12
Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol (2004) 1.11
Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol (2006) 1.10
Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury. Immunology (2004) 1.09
'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res (2002) 1.08
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine (2007) 1.07
Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun (2003) 1.06
Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol (2004) 1.06
Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World J Gastroenterol (2005) 1.06
Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol (2002) 1.06
Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther (2009) 1.05
Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol (2004) 1.05
Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infect Immun (2001) 1.05
Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One (2008) 1.04
DNA vaccines: improving expression of antigens. Genet Vaccines Ther (2003) 1.04
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04
Development of Vaccines against Visceral Leishmaniasis. J Trop Med (2011) 1.03
On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect Immun (2003) 1.02
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol (2011) 1.02
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02
DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02
Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J Virol (2001) 1.01
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine (2010) 1.00
TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl Trop Dis (2011) 1.00
Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect Immun (2002) 0.99
DNA vaccines to attack cancer. Proc Natl Acad Sci U S A (2004) 0.98
Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol (2004) 0.97
Evaluation of a novel non-penetrating electrode for use in DNA vaccination. PLoS One (2011) 0.96
Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun (2004) 0.96
Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol (2008) 0.95
Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther (2008) 0.95
Protective immunity and vaccination against cutaneous leishmaniasis. Front Immunol (2012) 0.95
Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine (2008) 0.94
Vaccines to prevent leishmaniasis. Clin Transl Immunology (2014) 0.94
A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol (2010) 0.93
A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas disease. Int J Biol Sci (2011) 0.93
Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92
DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun (2004) 0.92
Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis. Parasitol Res (2010) 0.92
Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults. Mol Ther (2011) 0.92
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol (2012) 0.92
Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther (2010) 0.91
Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect Immun (2005) 0.91
The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun (2003) 0.91
Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine (2008) 0.90
Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol (2001) 0.90
Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90
Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol (2001) 0.90
PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest (2013) 0.90
Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat (2012) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug. Infect Immun (2002) 0.89
Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci (2010) 0.89
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89
Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun (2002) 0.89
DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine (2010) 0.88
Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection. Infect Immun (2003) 0.88
DNA vaccines for cervical cancer. Am J Transl Res (2010) 0.88
Nano-biolistics: a method of biolistic transfection of cells and tissues using a gene gun with novel nanometer-sized projectiles. BMC Biotechnol (2011) 0.88
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci (2009) 0.88
Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther (2008) 0.87
Toward a modern synthesis of immunity: Charles A. Janeway Jr. and the immunologist's dirty little secret. Yale J Biol Med (2011) 0.87
DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett (2007) 0.87
Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. J Virol (2003) 0.87
Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One (2013) 0.87
Leishmania mexicana Gp63 cDNA Using Gene Gun Induced Higher Immunity to L. mexicana Infection Compared to Soluble Leishmania Antigen in BALB/C. Iran J Parasitol (2011) 0.86
Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers. Breast Cancer Res Treat (2010) 0.86
Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer (2009) 0.86
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Lymphocyte responses and cytokines. Cell (1994) 8.35
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Activation events during thymic selection. J Exp Med (1992) 3.43
Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med (2000) 3.07
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med (1997) 2.81
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol (2001) 2.61
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
Induction and regulation of IL-15 expression in murine macrophages. J Immunol (1996) 2.28
Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol (1994) 2.25
Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 2.23
Genomic DNA released by dying cells induces the maturation of APCs. J Immunol (2001) 2.03
Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med (1998) 1.99
IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol (1995) 1.94
Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest (1992) 1.84
Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med (1997) 1.73
The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol (2001) 1.72
Interleukin 4 suppresses interleukin 2 and interferon gamma production by naive T cells stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci U S A (1993) 1.71
Lymphokine and cytokine production by Fc epsilon RI+ cells. Adv Immunol (1993) 1.67
Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol (1999) 1.58
The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A (2000) 1.55
Distinct patterns of cytokine secretion characterize new onset synovitis versus chronic rheumatoid arthritis. J Rheumatol (1998) 1.55
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol (1998) 1.54
Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A (1999) 1.48
Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A (1994) 1.47
Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol (1996) 1.46
Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol (2000) 1.45
Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J Immunol (1985) 1.44
Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol (1998) 1.42
DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol (2000) 1.42
Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol (2001) 1.33
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 1.32
Autoimmunity and increased c-myb transcription. Science (1984) 1.27
Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol (1998) 1.26
Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol (1995) 1.24
Microbial products induce autoimmune disease by an IL-12-dependent pathway. J Immunol (1997) 1.21
Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine (1999) 1.20
CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. J Immunol (1998) 1.20
CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun (2000) 1.19
Proliferation of anti-DNA-producing NZB B cells in a non-autoimmune environment. J Immunol (1986) 1.17
Dealing from the evolutionary pawnshop: how lymphocytes make decisions. Immunity (1999) 1.15
Oncogene expression in autoimmune and normal peripheral blood mononuclear cells. J Exp Med (1986) 1.15
Effects of interleukin-3 with or without the c-kit ligand, stem cell factor, on the survival and cytoplasmic granule formation of mouse basophils and mast cells in vitro. Am J Pathol (1994) 1.13
CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with histoplasma capsulatum. J Exp Med (1998) 1.12
Patients with multidrug-resistant tuberculosis with low CD4+ T cell counts have impaired Th1 responses. J Immunol (1997) 1.10
T helper cell differentiation in immune response. Curr Opin Immunol (1995) 1.10
Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun (1998) 1.09
Regulation of transforming growth factor-beta production by interleukin-12. Eur J Immunol (1997) 1.09
Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest (1996) 1.08
Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr (1995) 1.08
Sequence analysis and expression of an X-linked, lymphocyte-regulated gene family (XLR). J Exp Med (1987) 1.07
Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology (2000) 1.06
NIH conference. Systemic lupus erythematosus. Ann Intern Med (1991) 1.06
IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J Clin Invest (1996) 1.05
Fc epsilon receptor-positive cells are a major source of antigen-induced interleukin-4 in spleens of mice infected with Schistosoma mansoni. Eur J Immunol (1993) 1.03
Theoretical and experimental approaches to generalized autoimmunity. Immunol Rev (1990) 1.03
Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest (1998) 1.03
Heterogeneous expression and coordinate regulation of endogenous retroviral sequences in human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses (1992) 1.02
Pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am (1988) 1.02
Cytokine regulation of IL-12 receptor beta2 expression: differential effects on human T and NK cells. Eur J Immunol (2000) 1.02
CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. Eur J Immunol (2001) 1.01
Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect Immun (1997) 0.99
CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. Cell Immunol (2000) 0.99
IgE receptor-positive non-B/non-T cells dominate the production of interleukin 4 and interleukin 6 in immunized mice. Proc Natl Acad Sci U S A (1995) 0.98
A suppressive oligodeoxynucleotide inhibits ocular inflammation. Clin Exp Immunol (2009) 0.98
Individual cells simultaneously produce both IL-4 and IL-6 in vivo. Cytokine (1994) 0.98
Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus (2001) 0.96
Toward clinical trials of DNA vaccines against malaria. Immunol Cell Biol (1997) 0.95
The interaction of the xid and me genes. J Immunol (1987) 0.95
Do DNA vaccines induce autoimmune disease? Hum Gene Ther (1997) 0.95
Autoantibody production is associated with polyclonal B cell activation in autoimmune mice which express the lpr or gld genes. Eur J Immunol (1988) 0.95
Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides. Rheumatology (Oxford) (2003) 0.95
Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport (2001) 0.95
NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med (1988) 0.93
Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-alpha in human peripheral blood. Cytokine (1995) 0.93
Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms. J Immunol (1999) 0.93
Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther (2005) 0.92
Murine cytomegalovirus infection-induced polyclonal B cell activation is independent of CD4+ T cells and CD40. Virology (1998) 0.92
Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol (1999) 0.90
Increased activation and altered ratio of interferon-gamma: interleukin-4 secreting cells in MRL-lpr/lpr mice. Autoimmunity (1995) 0.90
DNAse treatment does not improve the survival of lupus prone (NZB x NZW)F1 mice. Lupus (1998) 0.90
Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjögren's syndrome. J Rheumatol (1998) 0.90
Effect of HIV infection on the frequency of cytokine-secreting cells in human peripheral blood. AIDS Res Hum Retroviruses (1996) 0.90
The natural history of disease expression in CD4 and CD8 gene-deleted New Zealand black (NZB) mice. J Immunol (1996) 0.89
IFN-gamma is a potent inducer of Ig secretion by sort-purified murine B cells activated through the mIg, but not the CD40, signaling pathway. Int Immunol (1996) 0.89
Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J Immunol (1999) 0.88
Differential requirement of IFN consensus sequence binding protein for the production of IL-12 and induction of Th1-type cells in response to IFN-gamma. J Immunol (1999) 0.87
Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J Immunol (1998) 0.87
Idiotypy and autoimmunity. Arthritis Rheum (1986) 0.85
Genetic studies in NZB mice. VI. Association of autoimmune traits in recombinant inbred lines. J Immunol (1984) 0.84
Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. Vet Microbiol (2001) 0.84
Molecular and cellular determinants of immunity to Histoplasma capsulatum. Res Immunol (1998) 0.84
Contribution of interleukin-3 to antigen-induced Th2 cytokine production. Eur J Immunol (1996) 0.84
The regulation of IL-12: its role in infectious, autoimmune, and allergic diseases. J Allergy Clin Immunol (1998) 0.83